



MINUTES

**3RD BioEscalator Genetic Modification Safety Committee Meeting
held on Wednesday 13th November 2019, 10:00-11:00 Meeting Room 3, BioEscalator, Innovation
Building**

Present:

Khwaja Islam (Chair) (BioEscalator Biological Safety Officer)
Julie Hamilton (University Divisional Safety Officer)
Heather Brower (MiroBio Ltd)
Cathy Gouveia (MoA-Technology Ltd)
Danuta Jeziorska (Nucleome Therapeutics Ltd)
Duncan Howie (Ervaxx Ltd)

1. Apologies:

Claire Shingler (Observer) (BioEscalator Business Manager)
Graham Ross (University Divisional Safety Officer)
Kerry Fisher (Theolytics)
Kevin Maskell (Bioarchitech)
Len Seymour (Macrophox)

2. Note any conflict of interest:

KM who could not attend the meeting wanted to mention that he has no new risk assessment (RA) at present, but supports the motion to have an opt put process for similar companies due to conflicts of interest as it can jeopardise intellectual property (IP) on both sides. As example one company copying another company specific technology so happened to do the same thing. Nobody wants that legal risk to ones IP. Committee agreed we have the CDA in place already and everyone should when writing their RA for approval not to go into too much detail that will jeopardise their IP. To concentrate on the nature of work (i.e. contained use involving GM work) that will take place in the BioEscalator. There is a section on the HSE form that one can disclose more information should they wish too that will be exempt from public disclosure.

3. Introduction of Member:

Danuta Jeziorska was introduced to the Committee.

4. Minutes of the last meeting:

Minutes approved by committee members.

5. Outcome of HSE visit for MoA:

KI reported HSE visit took place on the 4th November 2019 and inspector was My Bryan Carlsen, regulatory compliance officer. Inspection commissioned by DEFRA because MoA recently registered as working with transgenic plants to assess the environmental aspects of activities with larger genetically modified (GM) organisms. Overall, it went well and the inspector was happy with the visit. See attached document **outcome of HSE inspection**.

6. Company departure:

KI informed that Macrophox have left the BioEscalator on 30/09/2009 and have now moved to Oxford Science Park in Littlemore. They have informed HSE of their new address.

7. Update on CDA:

It was agreed, any new companies who want to do any GM work, would need to be added the CDA before, any risk assessment could be circulated for approval by the committee. CG will amend the CDA once KI receive the details of company name and registered address. Once CDA has been amended, it will need to be signed off by the new companies.

Action:

Email KI with company name and company registered address to add to the CDA.

8. Approval of Risk Assessments prior to the meeting:

KI reported two contained use activities (risk assessments) approved prior to the meeting as follows:

- a) 1 x class 2 (Ervaxx)
- b) 1 X class 2 (MiroBio)

9. Any Other Business (AOB):

None

10. Date and venue of next meeting:

TBA for November 2020.